Canonic Ltd., focused on the development of medicinal cannabis products and subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), announced the launch of its new product line in Israel.
The first new product from the second generation product line is expected to be available to patients in early October 2022. Israel is one of the countries leading the way when it comes to the latest developments of medicinal cannabis products.
High THC content and genetic markers
Canonic's second generation products are characterized by high THC content and unique terpene profiles. THC is the main psychoactive ingredient in cannabis. Terpenes are plant compounds known to have complementary medicinal benefits, including anti-inflammatory, analgesia, anxiolytic, antidepressant, anti-insomnia, and more. They also affect the aroma and smell of the cannabis.
The new products have been developed through breeding programs conducted by Canonic over the past two years. They include the use of proprietary sets of new genetic markers. The use of genetic markers directs and speeds up the breeding process to achieve unique cannabis lines that meet the market requirements.
Arnon Heyman, Chief Executive Officer of Canonic: “We have been able to increase cannabinoid and terpene concentrations, which are known to relieve many symptoms. This was made possible using advanced computer technology, coupled with patented sets of novel genetic markers and other advanced breeding methods.”
Source: canonicbio.com (EN)
